Integrin alpha 4 beta 1

Integrin alpha 4 beta 1 Informations sur la molécule

Nom anglais	Integrin alpha-4/beta-1	Nombre de médicaments commercialisés	3
Nombre de médicaments cliniques	6	Alias de la cible	Integrin alpha4beta1
Phase de R&D la plus avancée	Approved

Nom anglais	Integrin alpha-4/beta-1
Alias de la cible	Integrin alpha4beta1
Nombre de médicaments commercialisés	3
Nombre de médicaments cliniques	6
Phase de R&D la plus avancée	Approved

Integrin alpha 4 beta 1 Liste de produits

Attribut
Protein (2)Kits (1)
Bibliothèque de produits
En ligne (3)
Espèces
Human (3)
Étiquette
His Tag (1)His Tag & Avi Tag (1)- (1)
Marqueur
Unconjugated (1)Biotin-labeled (1)- (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
AIDD‑Ready FRT-P049	Human	-	Human Integrin α4β1 / VCAM-1 Inhibitor Screening Kit (TR-FRET)	Ajouter au panier
IT1-H52W1	Human	HEK293	Human Integrin alpha 4 beta 1 (ITGA4&ITGB1) Heterodimer Protein, His Tag&Tag Free, low endotoxin	Ajouter au panier
IT1-H82W1	Human	HEK293	Biotinylated Human Integrin alpha 4 beta 1 (ITGA4&ITGB1) Heterodimer Protein, His,Avitag™&Tag Free	Ajouter au panier

Quantité totale3

Demande de produit

Integrin alpha 4 beta 1Contexte de la molécule

Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. Integrin alpha 4 beta 1(Alpha-4/beta-1) is receptors for fibronectin. Integrin alpha-4/beta-1 is a receptor for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1.

Integrin alpha 4 beta 1Alias de la molécule

Integrin alpha 4 beta 1,ITGA4&ITGB1

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Natalizumab biosimilar (GENERIUM Pharmaceuticals)	GNR-093	Phase 3 Clinical	Generium Pharmaceuticals	Multiple Sclerosis	Details
Avicursen	TV-1102; ATL/TV-1102; ATL-1102; ISIS-107248	Phase 2 Clinical	Ionis Pharmaceuticals Inc	Multiple Sclerosis; Muscular Dystrophy, Duchenne	Details
Alintegimod	7HP349; 7-HP-349; 7HP-349	Phase 2 Clinical	7 Hills Pharma LLC	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chagas Disease; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Influenza, Human; Kidney Neoplasms; Lymphoma; Melanoma; Mesothelioma; Mismatch Repair Deficient Cancer; Neoplasm Metastasis; Neoplasms; Skin Neoplasms; Solid tumours; Tuberculosis	Details
LLP2A alendronate		Phase 1 Clinical	University Of California	Bone Diseases; Bone Diseases, Metabolic; Osteonecrosis; Osteoporosis	Details
ABBV-243	ABBV-243	Phase 1 Clinical	Abbvie Inc		Details
RBx-7796	RBx-7796	Clinical	Sun Pharmaceutical Industries Ltd	Asthma; Rhinitis, Allergic	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Carotegrast methyl	AJM-300	Approved	Ea Pharma, Eisai Co Ltd	Carogra	Japan	Colitis, Ulcerative	Ea Pharma Co Ltd	2022-03-28	Colitis, Ulcerative	Details
Natalizumab biosimilar (Polpharma Biologics)	PB-006; DST-356A1	Approved	Polpharma Biologics Sa	Tyruko	United States	Multiple Sclerosis; Crohn Disease	Sandoz Inc	2023-08-24	Crohn Disease; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting	Details
Natalizumab	BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E	Approved	Biogen Inc, Perrigo Llc	Tysabri, Antegran, Antegren	United States	Crohn Disease; Multiple Sclerosis	Biogen Idec	2004-11-23	Arthritis, Rheumatoid; Crohn Disease; Demyelinating Diseases; Epilepsies, Partial; Graft vs Host Disease; Ischemic Stroke; Multiple Myeloma; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Myositis, Inclusion Body	Details